All In Biotech

Drug Trial Radar · NCT04975308

A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy

Last checked: Nov 20, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 874 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

874

Actual

Start

Oct 4, 2021

Primary completion

Jun 24, 2024

Study completion Aug 2027

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Jul 23, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy, and how well imlunestrant with abemaciclib work compared to imlunestrant in participants with breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have breast cancer that is advanced or has spread to another part of the body. Study participation could last up to 5 years.

Conditions

  • Breast Neoplasms
  • Neoplasm Metastasis

Interventions

  • ImlunestrantDrug

    Administered orally.

  • ExemestaneDrug

    Administered orally.

  • FulvestrantDrug

    Administered IM.

  • AbemaciclibDrug

    Administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Investigator-assessed Progression Free Survival (PFS) (Between Arm A and Arm B)Time frame: Randomization to the date of first documented progression of disease or death from any cause (up to 28 months)
  2. Investigator-assessed PFS (Between Arm C and Arm A)Time frame: Randomization to the date of first documented progression of disease or death from any cause (up to 26 months)
  3. Investigator-assessed PFS in the Estrogen Receptor 1 (ESR1)-Mutation Detected Population (Between Arm A and Arm B)Time frame: Randomization to the date of first documented progression of disease or death from any cause (up to 28 months)

Locations

243 sites in 22 countries. Site status is shown where the registry gives one.

  • Ironwood Cancer & Research Centers

    Chandler, Arizona

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona

  • Marin Cancer Care

    Greenbrae, California

  • University of California Davis (UC Davis) Comprehensive Cancer Center

    Sacramento, California

  • Sharp Memorial Hospital

    San Diego, California

  • Banner MD Anderson Cancer Center at McKee Medical Center

    Loveland, Colorado

  • Clermont Oncology Center

    Clermont, Florida

  • University of Florida College of Medicine

    Gainesville, Florida

  • Mid Florida Hematology and Oncology Center

    Orange City, Florida

  • Florida Cancer Specialists

    Sarasota, Florida

  • Florida Cancer Specialists

    St. Petersburg, Florida

  • Kaiser Permanente Moanalua Medical Center

    Honolulu, Hawaii

  • University of Chicago Medical Center

    Chicago, Illinois

  • NorthShore University HealthSystem - Evanston Hospital

    Evanston, Illinois

  • IU Health Ball Memorial Hospital, Inc.

    Muncie, Indiana

  • The University of Louisville, James Graham Brown Cancer Center

    Louisville, Kentucky

  • Jackson Oncology Associates, PLLC

    Jackson, Mississippi

  • Care Access - Clifton

    Clifton, New Jersey

  • Memorial Sloan Kettering - Bergen

    Montvale, New Jersey

  • Columbia University Medical Center

    New York, New York

  • University of North Carolina Medical Center

    Chapel Hill, North Carolina

  • Aultman Hospital

    Canton, Ohio

  • Mercy Health - St. Vincent Medical Center

    Toledo, Ohio

  • Avera Cancer Institute Sioux Falls

    Sioux Falls, South Dakota

  • Florida Cancer Specialists

    Nashville, Tennessee

  • The Mark H Zangmeister Cancer Center

    Nashville, Tennessee

  • USO - Texas Oncology - Allen

    Allen, Texas

  • Texas Oncology - Dallas Presbyterian Hospital

    Dallas, Texas

  • Willamette Valley Cancer Institute & Research Ctr.

    Houston, Texas

  • Texas Oncology - Carrollton

    Lewisville, Texas

  • Texas Oncology - Denison

    The Woodlands, Texas

  • Texas Oncology - Paris

    The Woodlands, Texas

  • Blue Ridge Cancer Care

    The Woodlands, Texas

  • Broome Oncology

    The Woodlands, Texas

  • Minnesota Oncology/Hematology PA

    The Woodlands, Texas

  • Texas Oncology - Carrollton

    The Woodlands, Texas

  • Texas Oncology - McKinney

    The Woodlands, Texas

  • Texas Oncology - Medical City Dallas

    The Woodlands, Texas

  • Texas Oncology - Methodist Charlton Cancer Center

    The Woodlands, Texas

  • Texas Oncology - San Antonio Medical Center

    The Woodlands, Texas

Showing 40 of 243 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.